Examorelin

Growth Hormone Secretagogue / GHRP (Growth Hormone Releasing Peptide)Rx: ResearchCompound: Investigational

Also known as: EP-23905, Examorelin acetate, Hexarelin, MF-6003

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Examorelin (hexarelin) is a potent synthetic hexapeptide GHRP that stimulates GH secretion via the ghrelin receptor. It has been investigated for GH deficiency, cardiac dysfunction, and cachexia. It is not approved for clinical use in any major jurisdiction but has been studied in numerous clinical trials.

Mechanism of Action

Synthetic hexapeptide that acts as a ghrelin mimetic, binding to the growth hormone secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus to stimulate pulsatile growth hormone release.

Routes of Administration

IntranasalIntravenousSubcutaneous

Goals & Uses

  • Cachexia / muscle wastingMetabolic / Body CompositionLow
  • Cardiac protection / dysfunctionCardiovascularModerate
  • Treatment of GH deficiencyEndocrine / TherapeuticModerate
  • IGF-1 elevationMetabolic / HormonalModerate
  • Growth hormone stimulationEndocrine / HormonalHigh

Contraindications

  • Active malignancyOncologyHighUse caution or avoid depending on agent and context
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data
  • Diabetic retinopathyOphthalmologyModerate
  • Acromegaly or gigantismEndocrineHigh

Adverse Effects

  • HypoglycemiaMetabolicRareAbnormally low blood glucose
  • Injection site reactionsLocalCommon
  • Carpal tunnel syndromeMusculoskeletalUncommon
  • Tachyphylaxis / GH desensitizationPharmacodynamicCommon
  • Water retention / edemaFluid BalanceUncommon
  • Cortisol and prolactin elevationEndocrineCommon

Drug Interactions

  • Insulin / antidiabetic agentsModerate
  • CorticosteroidsModerate
  • Somatostatin analogues (e.g., octreotide)Moderate

Population Constraints

  • Pediatric patientsAgeRelative
  • Athletes subject to WADA regulationsRegulatory / SportsAbsolute
  • Patients with diabetes mellitusMetabolicRelative
  • Elderly patientsAgeRelative

Regulatory Status

  • European UnionInvestigationalNot EMA approved. Has been studied in European clinical trials for GH deficiency and cardiac conditions.
  • United StatesInvestigationalNot FDA approved. Investigational use only; no active IND publicly listed for current development.
  • United KingdomUnapprovedNot approved by MHRA. Classified as a research compound; prohibited in sport by WADA/UKAD.

Not approved by FDA, EMA, or MHRA for any indication. Investigated in clinical trials for GH deficiency and cardiac conditions. Classified as a research/investigational compound. Listed as a prohibited substance by WADA.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack